A universal flu vaccine

Acta Biochimica Polonica

Volumn 61, Issue 3, 2014, Pages 523-530

  Kesik Brodacka, Malgorzata ^a   Plucienniczak, Grazyna ^a  

^a INDUSTRIAL CHEMISTRY RESEARCH INSTITUTE   (Poland)

Author keywords

Flu vaccine; Influenza virus; Universal vaccine

Indexed keywords

FLU VACCINE; ORTHOMYXOVIRIDAE;

INFLUENZA VACCINE; VIRUS ANTIGEN;

GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA VIRUS A; INFLUENZA, HUMAN; VACCINATION;

ANTIGENS, VIRAL; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINATION;

EID: 84907693704     PISSN: 0001527X     EISSN: 1734154X     Source Type: Journal    
DOI: 10.18388/abp.2014_1874     Document Type: Review

References (126)

1. Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC (2011) Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis 52: 1-7.
2. Bessa J, Schmitz N, Hinton HJ, Schwarz K, Jegerlehner A, Bachmann MF (2008) Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 38: 114-126.
3. Blank PR, Bonnelye G, Ducastel A, Szucs TD (2012) Attitudes of the general public and general practitioners in five countries towards pandemic and seasonal influenza vaccines during season 2009/2010. PLoS One 7: e45450.
4. Bommakanti G, Citron MP, Hepler RW, Callahan C, Heidecker GJ, Najar TA, Lu X, Joyce JG, Shiver JW, Casimiro DR, ter Meulen J, Liang X, Varadarajan R (2010) Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA 107: 13701-13706.
5. Boyd AC, Ruiz-Hernandez R, Peroval MY, Carson C, Balkissoon D, Staines K, Turner AV, Hill AV, Gilbert SC, Butter C (2013) Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus. Vaccine 31: 670-675.
6. Brewoo JN, Powell TD, Jones JC, Gundlach NA, Young GR, Chu H, Das SC, Partidos CD, Stinchcomb DT, Osorio JE (2013) Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine 31: 1848-1855.
7. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181: 4168-4176.
8. Carrat F, Flahault A (2007) Influenza vaccine: the challenge of antigenic drift. Vaccine 25: 6852-6862.
9. Chen MW, Cheng TJ, Huang Y, Jan JT, Ma SH, Yu AL, Wong CH, Ho DD (2008) A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc Natl Acad Sci USA 105: 13538-13543.
10. Clementi N, De Marco D, Mancini N, Solforosi L, Moreno GJ, Gubareva LV, Mishin V, Di Pietro A, Vicenzi E, Siccardi AG, Clementi M, Burioni R (2011) A human monoclonal antibody with neutralizing activity against highly divergent influenza subtypes. PLoS One 6: e28001.
11. Corti D, Lanzavecchia A (2013) Broadly neutralizing antiviral antibodies. Annu Rev Immunol 31: 705-742.
12. Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A (2010) Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest 120: 1663-1673.
13. Corti D, Voss J, Gamblin SJ, Codoni G, Macagno A, Jarrossay D, Vachieri SG, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez BM, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire LF, Temperton N, Langedijk JP, Skehel JJ, Lanzavecchia A (2011) A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333: 850-856.
14. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED (1974) Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 129: 411-420.
15. Cox NJ, Subbarao K (1999) Influenza. Lancet 354: 1277-1282.
16. de Filette M, Min Jou W, Birkett A, Lyons K, Schultz B, Tonkyro A, Resch S, Fiers W (2005) Universal influenza A vaccine: optimization of M2-based constructs. Virology 337: 149-161.
17. de Filette M, Ramne A, Birkett A, Lycke N, Löwenadler B, Min Jou W, Saelens X, Fiers W (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24: 544-551.
18. de Jong JC, Beyer WE, Palache AM, Rimmelzwaan GF, Osterhaus AD (2000) Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly. J Med Virol 61: 94-99.
19. Dreyfus C, Laursen NS, Kwaks T, Zuijdgeest D, Khayat R, Ekiert DC, Lee JH, Metlagel Z, Bujny MV, Jongeneelen M, van der Vlugt R, Lamrani M, Korse HJ, Geelen E, Sahin Ö, Sieuwerts M, Brakenhoff JP, Vogels R, Li OT, Poon LL, Peiris M, Koudstaal W, Ward AB, Wilson IA, Goudsmit J, Friesen RH (2012) Highly conserved protective epitopes on influenza B viruses. Science 337: 1343-1348.
20. Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M Goudsmit J, Wilson IA (2009) Antibody recognition of a highly conserved influenza virus epitope. Science 324: 246-251.
21. Ekiert DC, Friesen RH, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse HJ, Brandenburg B, Vogels R, Brakenhoff JP, Kompier R, Koldijk MH, Cornelissen LA, Poon LL, Peiris M, Koudstaal W, Wilson IA, Goudsmit J (2011) A highly conserved neutralizing epitope on group 2 influenza a viruses. Science 333: 843-850.
22. Ekiert DC, Kashyap AK, Steel J, Rubrum A, Bhabha G, Khayat R, Lee JH, Dillon MA, O'Neil RE, Faynboym AM, Horowitz M, Horowitz L, Ward AB, Palese P, Webby R, Lerner RA, Bhatt RR, Wilson IA (2012) Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature 489: 526-532.
23. El Bakkouri K, Descamps F, De Filette M, Smet A, Festjens E, Birkett A, Van Rooijen N, Verbeek S, Fiers W, Saelens X (2001) Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186: 1022-1031.
24. Epstein SL (2003) Control of influenza virus infection by immunity to conserved viral features. Expert Rev Anti-Infect Ther 1: 627-638.
25. Epstein SL, Price GE (2010) Cross-protective immunity to influenza A viruses. Expert Rev Vaccines 9: 1325-1341.
26. Ernst WA, Kim HJ, Tumpey TM, Jansen AD, Tai W, Cramer DV, Adler-Moore JP, Fujii G (2006) Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 24: 5158-5168.
27. Fan J, Liang X, Horton MS, Perry HC, Citron MP, Heidecker GJ, Fu TM, Joyce J, Przysiecki CT, Keller PM, Garsky VM, Ionescu R, Rippeon Y, Shi L, Chastain MA, Condra JH, Davies ME, Liao J, Emini EA, Shiver JW (2004) Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22: 2993-3003.
28. Fiers W, De Filette M, Birkett A, Neirynck S, Min Jou W (2004) A "universal" human influenza A vaccine. Virus Res 103: 173-176.
29. Fiore AE, Uyeki TM, Broder K, Finelli L, Euler GL, Singleton JA, Iskander JK, Wortley PM, Shay DK, Bresee JS, Cox NJ (2010) Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. Centers for Disease Control and Prevention (CDC) MMWR Recomm Rep 59: 1-62.
30. Friesen RH, Lee PS, Stoop EJ, Hoffman RM, Ekiert DC, Bhabha G, Yu W, Juraszek J, Koudstaal W, Jongeneelen M, Korse HJ, Ophorst C, Brinkman-van der Linden EC, Throsby M, Kwakkenbos MJ, Bakker AQ, Beaumont T, Spits H, Kwaks T, Vogels R, Ward AB, Goudsmit J, Wilson IA (2014) A common solution to group 2 influenza virus neutralization. Proc Natl Acad Sci U S A 111: 445-450.
31. Fu TM, Grimm KM, Citron MP, Freed DC, Fan J, Keller PM, Shiver JW, Liang X, Joyce JG (2009) Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27:1440-1447.
32. Gerhard W, Mozdzanowska K, Zharikova D (2006) Prospects for universal influenza virus vaccine. Emerg Infect Dis 12: 569-574.
33. Hampson AW, Mackenzie JS (2006) The influenza viruses. Med J Aust 185: S39-S43.
34. Han T, Marasco WA (2011) Structural basis of influenza virus neutralization. Ann NY Acad Sci 1217: 178-190.
35. Hay AJ, Gregory V, Douglas AR, Lin YP (2001) The evolution of human influenza viruses. Philos Trans R Soc Lon B Biol Sci 356: 1861-1870.
36. Hayashida H, Toh H, Kikuno R, Miyata T (1985) Evolution of influenza virus genes. Mol Biol Evol 2 :289-303.
37. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT (2002) Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacer-bates disease after challenge with influenza A virus. J Gen Virol 83: 1851-1859.
38. Heiny AT, Miotto O, Srinivasan KN, Khan AM, Zhang GL, Brusic V, Tan TW, August JT (2007) Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One 2: e1190.
39. Hessel A, Savidis-Dacho H, Coulibaly S, Portsmouth D, Kreil TR, Crowe BA, Schwendinger MG, Pilz A, Barrett PN, Falkner FG, Schäfer B (2014) MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses. PLoS One 9: e88340.
40. Hikono H, Miyazaki A, Mase M, Inoue M, Hasegawa M, Saito T (2012) Induction of a cross-reactive antibody response to influenza virus m2 antigen in pigs by using a sendai virus vector. Vet Immunol Immunopathol 146: 92-96.
41. Hoag H (2013) A universal problem. Nature Medicine 19: 12-14.
42. Huber VC (2013) Influenza vaccines: From whole virus preparations to recombinant protein technology. Expert Rev Vaccine 13: 31-42.
43. Huleatt JW, Nakaar V, Desai P, Huang Y, Hewitt D, Jacobs A, Tang J, McDonald W, Song L, Evans RK, Umlauf S, Tussey L, Powell TJ (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26: 201-214.
44. Ionescu RM, Przysiecki CT, Liang X, Garsky VM, Fan J, Wang B, Troutman R, Rippeon Y, Flanagan E, Shiver J, Shi L (2006) Pharmaceutical and immunological evaluation of human papilloma virus virus like particle as an antigen carrier. J Pharm Sci 95: 70-79.
45. Jefferson T, Di Pietrantonj C, Rivetti A, Bawazeer GA, Al-Ansary LA, Ferroni E (2010) Vaccines for preventing influenza in healthy adults. Cochrane Database Sys Rev 7: CD001269.
46. Jegerlehner A, Schmitz N, Storni T, Bachmann MF (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172: 5598-5605.
47. Johansson BE, Cox MM (2011) Influenza viral neuraminidase: the forgotten antigen. Expert Rev Vaccines 10: 1683-1695.
48. Kanegae Y, Sugita S, Endo A, Ishida M, Senya S, Osako K, Nerome K, Oya A (1990) Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season. J Virol 64: 2860-2865.
49. Kashyap AK, Steel J, Oner AF, Dillon MA, Swale RE, Wall KM, Perry KJ, Faynboym A, Ilhan M, Horowitz M, Horowitz L, Palese P, Bhatt RR, Lerner RA (2008) Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A. 105: 5986-91.
50. Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H (2013) Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 5: 200ra114.
51. Kilbourne ED, Laver WG, Schulman JL, Webster RG (1968) Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 2: 281-288.
52. Kim MC, Song JM, O E, Kwon YM, Lee YJ, Compans RW, Kang SM (2013) Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol Ther 21: 485-492.
53. Kissling E, Valenciano M, Buchholz U, Larrauri A, Cohen JM, Nunes B, Rogalska J, Pitigoi D, Paradowska-Stankiewicz I, Reuss A, Jiménez-Jorge S, Daviaud I, Guiomar R, O'Donnell J, Necula G, Gluchowska M, Moren A (2014) Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13. Eurosurveillance 19.
54. Kissling E, Valenciano M (2011) I-MOVE case-control studies team. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Eurosurveillance 16.
55. Kissling E, Valenciano M, Cohen JM, Oroszi B, Barret AS, Rizzo C, Stefanoff P, Nunes B, Pitigoi D, Larrauri A, Daviaud I, Horvath JK, O'Donnell J, Seyler T, Paradowska-Stankiewicz IA, Pechirra P, Ivanciuc AE, Jiménez-Jorge S, Savulescu C, Ciancio BC, Moren A (2011) I-MOVE multi-centre case control study 2010-11: overall and stratified estimates of influenza vaccine effectiveness in Europe. PLoS One 6: e27622.
56. Krammer F, Palese P (2014) Universal influenza virus vaccines: need for clinical trials. Nat Immunol 15: 3-5.
57. Krammer F, Pica N, Hai R, Tan GS, Palese P (2012) Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J Virol 86: 10302-10307.
58. Krystal M, Elliott RM, Benz EW Jr, Young JF, Palese P (1982) Evolution of influenza A and B viruses: Conservation of structural features in the hemagglutinin genes. Proc Natl Acad Sci U S A 79: 4800-4804.
59. Lamb RA, Krug RM (2001) Orthomyxoviridae: the viruses and their replication. In Fields Virology. Knipe DM, Howley PM, Griffin DE, eds, pp 1487-1531. Lippincott, Philadelphia.
60. Lamb RA, Zebedee SL, Richardson CD (1985) Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40: 627-633.
61. Lee PS, Yoshida R, Ekiert DC, Sakai N, Suzuki Y, Takada A, Wilson IA (2012) Heterosubtypic antibody recognition of the influenza virus hemagglutinin receptor binding site enhanced by avidity. Proc Natl Acad Sci USA 109: 17040-17045.
62. Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC (2012) Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans. Clin Infect Dis 55: 19-25.
63. Liu W, Zou P, Ding J, Lu Y, Chen YH (2005) Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. Microbes Infect 7:171-177.
64. Lu Y, Welsh JP, Swartz JR (2014) Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc Natl Acad Sci U S A 111: 125-130.
65. McMichael AJ, Gotch FM, Noble GR, Beare PA (1983) Cytotoxic T-cell immunity to influenza. N Engl J Med 309: 13-17.
66. Medina R A, A. Garcia-Sastre (2011) Influenza A viruses: new research developments. Nature reviews Microbiology 9: 590-603.
67. Mereckiene J, Cotter S, Nicoll A, Lopalco P, Noori T, Weber JT, D'Ancona F, Lévy-Bruhl D, Dematte L, Giambi C, Valentiner-Branth P, Stankiewicz I, Appelgren E, O'Flanagan D, the VENICE project gatekeepers group (2014) Seasonal influenza immunisation in Europe. Overview of recommendation and vaccination coverage for three seasons pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11). Eurosurveillance 19.
68. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P (2013) 1976 and 2009 H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans. J Infect Dis 207: 98-105.
69. Moriuchi H, Katsushima N, Nishimura H, Nakamura K, Numazaki Y (1991) Community-acquired influenza C virus infection in children. J Pediatr118: 235-238.
70. Murphy BR, Kasel JA, Chanock RM 1972) Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 286: 1329-1332.
71. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5: 1157-1163.
72. Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E (2007) Effectiveness of influenza vaccine in the community-dwelling elderly. N Engl J Med 357: 1373-1381.
73. Nicoll A, Sprenger M (2013) Low effectiveness undermines promotion of seasonal influenza vaccine. Lancet Infect Dis 13: 7-9.
74. Ohshima N, Iba Y, Kubota-Koketsu R, Asano Y, Okuno Y, Kurosawa Y (2011) Naturally occurring antibodies in humans can neutralize a variety of influenza virus strains, including H3, H1, H2, and H5. J Virol 85: 11048-11057.
75. Okuno Y, Isegawa Y, Sasao F, Ueda S (1993) A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol 67: 2552-2558.
76. Osterholm MT, Kelley NS, Sommer A, Belongia EA (2012) Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 12: 36-44.
77. Peter D Kwong, Ian A Wilson (2009) HIV-1 and influenza antibodies: seeing antigens in new ways. Nat Immunol 10: 573-578.
78. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, García-Sastre A, Palese P (2012) Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci USA 109: 2573-2578.
79. Pica N, Palese P (2013) Toward a universal influenza virus vaccine: Prospects and challenges. Ann Rev Med 64: 189-202.
80. Powers DC, Kilbourne ED, Johansson BE (1996) Neuraminidase-specific antibody responses to inactivated influenza virus vaccine in young and elderly adults. Clin Diagn Lab Immunol 3: 511-516.
81. Price GE, Lo CY, Misplon JA, Epstein SL (2014) Mucosal immunization with a candidate universal influenza vaccine reduces virus transmission in a mouse model. J Virol 88: 6019-6030.
82. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, Houser KV, Tumpey TM, Epstein SL (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27: 6512-6521.
83. Quan FS, Kim MC, Lee BJ, Song JM, Compans RW, Kang SM (2012) Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 430: 127-135.
84. Reid AH, Fanning TG, Janczewski TA, McCall S, Taubenberger JK (2012) Characterization of the 1918 "Spanish" influenza virus matrix gene segment. J Virol. 76: 10717-10723.
85. Rossman JS, Lamb RA (2011) Influenza virus assembly and budding. Virology 411: 229-236.
86. Rota PA, Wallis TR, Harmon MW, Rota JS, Kendal AP, Nerome K. (1990) Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology 175: 59-68.
87. Russ G, Poláková K, Kostolanskỳ F, Styk B, Vancíková M (1987) Monoclonal antibodies to glycopolypeptides HA1 and HA2 of influenza virus haemagglutinin. Acta Virol 31: 374-386.
88. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, Gust ID, Hampson AW, Hay AJ, Hurt AC, de Jong JC, Kelso A, Klimov AI, Kageyama T, Komadina N, Lapedes AS, Lin YP, Mosterin A, Obuchi M, Odagiri T, Osterhaus AD, Rimmelzwaan GF, Shaw MW, Skepner E, Stohr K, Tashiro M, Fouchier RA, Smith DJ (2008) Influenza vaccine strain selection and recent studies on the global migration of seasonal influenza viruses. Vaccine 26: 31-34.
89. Russell CJ (2011) Stalking influenza diversity with a universal antibody. N Engl J Med 365: 1541-1542.
90. Sagawa H, Ohshima A, Kato I, Okuno Y, Isegawa Y. (1996) The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J Gen Virol 77: 1483-1487.
91. Sakabe S, Iwatsuki-Horimoto K, Horimoto T, Nidom CA, Le MQ, Takano R, Kubota-Koketsu R, Okuno Y, Ozawa Kawaoka Y (2010) A cross-reactive neutralizing monoclonal antibody protects mice from H5N1 and pandemic (H1N1) 2009 virus infection. Antiviral Res 88: 249-255.
92. Schneemann A, Speir JA, Tan GS, Khayat R, Ekiert DC, Matsuoka Y, Wilson IA (2012) A Virus-like particle that elicits cross-reactive antibodies to the conserved stem of influenza virus hemagglutinin. J Virol 86: 11686-11697.
93. Schnell JR, Chou JJ (2008) Structure and mechanism of the M2 proton channel of influenza A virus. Nature 451: 591-595.
94. Scuffham PA, West PA (2002) Economic evaluation of strategies for the control and management of influenza in Europe. Vaccine 20: 2562-2578.
95. Shapshak P, Chiappelli F, Somboonwit C, Sinnott J (2011) The influenza pandemic of 2009: Lessons and implications. Mol Diagn Ther 15: 63-81.
96. Shu LL, Bean WJ, Webster RG (1993) Analysis of the evolution and variation of the human influenza A virus nucleoprotein gene from 1933 to 1990. J Virol 67: 2723-2729.
97. Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, Fonseca K, Winter AL, Gubbay JB, Krajden M, Petric M, Charest H, Bastien N, Kwindt TL, Mahmud SM, Van Caeseele P, Li Y (2014) Low 2012-13 Influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One 9: e92153.
98. Slepushkin VA, Katz JM, Black RA, Gamble WC, Rota PA, Cox NJ (1995) Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 13: 1399-1402.
99. Smirnov YA, Lipatov AS, Gitelman AK, Okuno Y, Van Beek R, Osterhaus AD, Claas EC (1999) An epitope shared by the hemagglutinins of H1, H2, H5, and H6 subtypes of influenza A virus. Acta Virol 43: 237-244.
100. Song JM, Wang BZ, Park KM, Van Rooijen N, Quan FS, Kim MC, Jin HT, Pekosz A, Compans RW, Kang SM (2011) Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6: e14538.
101. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, García-Sastre A, Palese P. (2010) Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1: e00018-10.
102. Subbarao K, Matsuoka Y. Trends Microbiol (2013) The prospects and challenges of universal vaccines for influenza. Trends Microbiol 21: 350-358.
103. Sui J, Hwang WC, Perez S, Wei G, Aird D, Chen LM, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox NJ, Bankston LA, Donis RO, Liddington RC, Marasco WA (2009) Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol 16: 265-273.
104. Sui J, Sheehan J, Hwang WC, Bankston LA, Burchett SK, Huang CY, Liddington RC, Beigel JH, Marasco WA (2011) Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza A antibodies. Clin Infect Dis 52: 1003-1009.
105. Talbot HK, Rock MT, Johnson C, Tussey L, Kavita U, Shanker A, Shaw AR, Taylor DN (2010) Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 5: e14442.
106. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K (2004) Influenza-associated hospitalizations in the United States. JAMA 292: 1333-1340.
107. Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, Goudsmit J (2008) Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3: e3942.
108. To KK, Zhang AJ, Hung IF, Xu T, Ip WC, Wong RT, Ng JC, Chan JF, Chan KH, Yuen KY (2012) High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin Vaccine immunol 19: 1012-1018.
109. Tompkins SM, Zhao ZS, Lo CY, Misplon JA, Liu T, Ye Z, Hogan RJ, Wu Z, Benton KA, Tumpey TM, Epstein SL (2007) Matrix protein 2 vac- cination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426-435.
110. Tong S, Zhu X, Li Y, Shi M, Zhang J, Bourgeois M, Yang H, Chen X, Recuenco S, Gomez J, Chen LM, Johnson A, Tao Y, Dreyfus C, Yu W, McBride R, Carney PJ, Gilbert AT, Chang J, Guo Z, Davis CT, Paulson JC, Stevens J, Rupprecht CE, Holmes EC, Wilson IA, Donis RO (2013) New world bats harbor diverse influenza a viruses. PLoS Pathog 9.
111. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR (1990) Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 64: 1375-1377.
112. Tsibane T, Ekiert DC, Krause JC, Martinez O, Crowe JE Jr, Wilson IA, Basler CF (2012) Influenza human monoclonal antibody 1F1 interacts with three major antigenic sites and residues mediating human receptor specificity in H1N1 viruses. PLoS Patog 8: e1003067
113. Turley CB, Rupp RE, Johnson C, Taylor DN, Wolfson J, Tussey L, Kavita U, Stanberry L, Shaw A (2011) Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29: 5145-5152.
114. Ulmer JB, Fu TM, Deck RR, Friedman A, Guan L, DeWitt C, Liu X, Wang S, Liu MA, Donnelly JJ, Caulfield MJ (1998) Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72: 5648-5653.
115. Wang R, Song A, Levin J, Dennis D, Zhang NJ, Yoshida H, Koriazova L, Madura L, Shapiro L, Matsumoto A, Yoshida H, Mikayama T, Kubo RT, Sarawar S, Cheroutre H, Kato S (2008) Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 80: 168-177.
116. Wang TT, Tan GS, Hai R, Pica N, Ngai L, Ekiert DC, Wilson IA, García-Sastre A, Moran TM, Palese P (2010) Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA 107: 18979-18984.
117. Weaver EA, Rubrum AM, Webby RJ, Barry MA (2011) Protection against divergent influenza H1N1 virus by a centralized influenza hemagglutinin. PLoS One 6: e18314.
118. Webster RG, Reay PA, Laver WG (1988) Protection against lethal influenza with neuraminidase. Virology 164: 230-237.
119. Wiley DC, Wilson IA, Skehel JJ (1981) Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 289: 373-378.
120. Wright PF, Webster RG (2001) Orthomyxoviridae: the viruses and their replication. In Fields Virology. Knipe DM, Howley PM, Griffin DE, eds, pp 1533-1579. Lippincott, Philadelphia.
121. Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW. (2012) A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus. PLoS One 7: e42363.
122. Wu F, Huang JH, Yuan XY, Huang WS, Chen YH (2007) Characterization of immunity induced by M2e of influenza virus. Vaccine 25: 8868-8873.
123. Wu F, Yuan XY, Li J, Chen YH (2009) The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine 27: 4320-4324.
124. Yogev R (2005) Influenza vaccine confusion: a call for an alternative evidence-based approach. Pediatrics 116: 1214-1215.
125. Zebedee S L, Lamb R A (1988) Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 62: 2762-2772.
126. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK (2012) Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 54: 1427-1436.